FRACTYL HEALTH, INC.
Developing gut-targeted endoscopic and gene therapies for obesity and type 2 diabetes.
GUTS | US
Overview
Corporate Details
- ISIN(s):
- US35168W1036
- LEI:
- Country:
- United States of America
- Address:
- 3 VAN DE GRAAFF DRIVE, 1803 BURLINGTON
- Website:
- https://www.fractyl.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Fractyl Health, Inc. is a metabolic therapeutics company focused on developing disease-modifying therapies for obesity and type 2 diabetes. The company's approach targets the root causes of these conditions in the gut, specifically the duodenum and pancreas, aiming to provide durable, disease-reversing treatments and reduce reliance on chronic drug regimens. Fractyl Health is advancing two primary platforms: Revita®, an investigational outpatient endoscopic procedure designed to resurface the duodenal lining, and Rejuva®, a one-time gene therapy platform in early development engineered to target pancreatic islet cells. The company's goal is to offer patients long-term freedom from metabolic diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all FRACTYL HEALTH, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for FRACTYL HEALTH, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for FRACTYL HEALTH, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
